Dermata Therapeutics (DRMA) Convertible Debt (2020 - 2021)
Dermata Therapeutics (DRMA) posted quarterly Convertible Debt of $174844.0 for Q2 2021, down 90.54% quarter-over-quarter from $1.8 million in Q4 2020.
Dermata Therapeutics (DRMA) Convertible Debt (2020 - 2021) Analysis & Trends
Dermata Therapeutics' Convertible Debt history runs 2 years deep, the most recent figure standing at $174844.0 for Q2 2021.
- In Q2 2021, Convertible Debt changed N/A year-over-year to $174844.0; the TTM figure through Jun 2021 stood at $174844.0 (changed N/A YoY), while the FY2020 annual figure was $1.8 million, changed N/A from the prior year.
- Convertible Debt for Q2 2021 stood at $174844.0, down from $1.8 million in the prior quarter.
- The five-year high for Convertible Debt was $1.8 million in Q4 2020, with the low at $174844.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - |
| 10 | Dermata Therapeutics | 5.60 Mn | 5.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 174,844.00 |
| Dec 31, 2020 | 1.85 Mn |